CAR-T CELL THERAPY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-109535 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

CAR-T Cell Therapy Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL CAR-T CELL THERAPY MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CAR-T CELL THERAPY MARKET

7.1 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL CAR-T CELL THERAPY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Bluebird Bio (US)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Celgene Corporation (US)

16.3 Gilead Sciences, Inc. (US)

16.4 Cellectis (France)

16.5 Servier Laboratories (France)

16.6 Pfizer Inc. (US)

16.7 Mereck KGaA (Germany)

16.8 Amgen Inc. (US)

16.9 Intellia Therapeutics (US)

16.10 Novartis International AG (Swiss)

16.11 Caribou Biosciences,Inc.(US)

16.12 Celyad (Belgium)

16.13 Bellicum Pharmaceuticals,Inc.(US)

16.14 Noile-Immune Biotech (Japan)

16.15 Nanjing Legend Biotechnology Co.,Ltd.(China)

16.16 Johnson & Johnson (US)

16.17 Sangamo Therapeutics,Inc.(US)

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Targeted Antigen
CD 19
BCMA
HER2
GD2
CD 20
CD22
CD30
CD33
HER1
Others

By Therapeutic Application
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Glioblastoma
Sarcoma
Neuroblastoma
Acute Myeloid Leukemia
Breast Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Colorectal Cancer
Others

Companies

Bluebird Bio (US)
Celgene Corporation (US)
Gilead Sciences, Inc. (US)
Cellectis (France)
Servier Laboratories (France)
Pfizer Inc. (US)
Mereck KGaA (Germany)
Amgen Inc. (US)
Intellia Therapeutics (US)
Novartis International AG (Swiss)
Caribou Biosciences,Inc.(US)
Celyad (Belgium)
Bellicum Pharmaceuticals,Inc.(US)
Noile-Immune Biotech (Japan)
Nanjing Legend Biotechnology Co.,Ltd.(China)
Johnson & Johnson (US)
Sangamo Therapeutics,Inc.(US)

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.